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The repressive and activating states of nuclear hor-
mone receptors are achieved through the recruitment of
cofactor proteins. The binding of co-repressors and co-
activators is believed to be mutually exclusive and prin-
cipally regulated by ligand binding. To understand the
molecular determinants of the switch induced by ligand
in the retinoic acid receptor and in particular the intrin-
sic role of the ligand binding domain (LBD) in cofactor
binding and release, we carried out extensive muta-
tional analysis of surface residues of the LBD. As seen
previously we found that co-repressor and co-activator
molecules bind to overlapping docking sites on the sur-
face of the retinoic acid receptor  LBD. Perturbation of
this surface impaired both co-activator and co-repressor
association resulting in a transcriptionally inert recep-
tor. Unexpectedly mutation of two residues, Trp-225 and
Ala-392, which lie outside the docking site, had opposite
effects on co-activator and co-repressor binding. W225A
was a constitutive repressor that failed to bind co-acti-
vator and exhibited an increased, and ligand-insensi-
tive, interaction with co-repressor. A392R, on the other
hand, had reduced affinity for co-repressors and in-
creased affinity for co-activators and behaved as a con-
stitutive, but still ligand-inducible, activator. Analysis
of known structures showed that these mutations lie in
the proximity of helix 12 (H12), and their effects are
likely to be the result of perturbations in the behavior of
H12. These data suggest that residues in the close vicin-
ity of H12 regulate cofactor affinity and determine the
basal activity of receptors.
Nuclear hormone receptors are ligand-activated transcrip-
tion factors that regulate gene expression as monomers, ho-
modimers, or heterodimers either by directly interacting with
DNA response elements or through “cross-talk” interactions
with other signaling pathways (1, 2). Among these receptors
the retinoic acid receptor (RAR)1 has a central role in a number
of cellular and physiological events such as epithelial and my-
eloid cell differentiation, reproduction, embryonic and adult
development, and also regeneration of several tissues and or-
gans (3–6). RAR heterodimerizes with the retinoid X receptor
(RXR) (7) and induces repression or activation of target genes
in response to receptor-specific ligands (8). Both the repressive
and active states of the receptor appear to be critical for the
biological functions of RAR.
In common with other nuclear receptors, RAR regulates gene
expression in response to ligands through the direct recruit-
ment of co-regulator proteins (for reviews, see Refs. 9–11). In
the presence of agonists, the receptor binds co-activator pro-
teins (such as ACTR, DRIP, and steroid receptor coactivator-1)
(12–14). These in turn associate with additional proteins form-
ing large complexes that activate transcription through
interaction with basal transcription factors and chromatin-
remodeling enzymes (e.g. histone acetyltransferases and meth-
yltransferases) providing the mechanistic and enzymatic re-
quirements for transcriptional activation (15–17). In the
absence of agonists, RAR binds co-repressor proteins (such as
SMRT and nuclear receptor co-repressor (N-CoR)) (18–20).
Again these form multicomponent repression complexes with
enzymatic activities such as histone deacetylation that result
in transcriptional repression (21, 22).
Recent studies have shown that both co-activator and co-
repressor proteins contain short sequence motifs (termed inter-
action domains (IDs)) that are necessary and sufficient to me-
diate the association of these cofactors with nuclear receptors.
Co-activators contain between one and five IDs with a consen-
sus sequence of LXXLL (23). These motifs are able to form
short amphipathic -helices that bind to the surface of the
nuclear receptor ligand binding domain (LBD) (24–26). In an
analogous fashion, co-repressor proteins have been found to
contain two or three motifs with a similar consensus sequence
of LXX(I/H)IXXX(I/L) (27–31). This motif also adopts an am-
phipathic -helical conformation but is somewhat longer than
the co-activator motif (32).
Our understanding of how ligand binding leads to the acti-
vation of nuclear receptors has been greatly advanced by struc-
tural studies of nuclear receptor ligand binding domains and
their interactions with co-activator and co-repressor peptides
(24–26, 32–34). The ligand binding domain is a predominantly
-helical domain with a large non-polar cavity, which can ac-
commodate lipophilic ligands. This cavity is capped by the
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C-terminal helix of the receptor (helix 12). In the active posi-
tion, helix 12 adopts a conformation such that it lies across
helices 3 and 10/11. This position favors binding of the -helical
co-activator in a perpendicular, largely non-polar, groove on the
receptor surface (24–26). A conserved glutamate within helix
12 contributes to a charge clamp interaction with the co-acti-
vator helix dipole. Importantly antagonists appear to function
through preventing helix 12 from adopting this active position
(26, 33, 35) and in some cases favor co-repressor binding to the
ligand binding domain in a position very similar to that of
co-activator (32) but without the active conformation of helix
12. The structural studies of cofactorreceptor interactions have
been supported by various biochemical approaches, particu-
larly for TR and RXR (36–39). For these receptors cofactor
binding sites were determined using site-directed mutagenesis,
mammalian two-hybrid analysis, and in vitro interaction
assays.
These biochemical and structural studies have given us a
good understanding of the mechanisms of cofactor recruitment.
However, one critical question that remains to be answered is
what determines the balance between repression and activa-
tion. It is clear that this varies enormously between different
nuclear receptors, and since these various receptors share a
common group of cofactors, understanding how this different
balance is achieved is of great biological significance. RAR and
TR lie at one extreme of this balance since they strongly re-
press gene expression in the absence of ligand (18–20, 40).
Receptors such as PPAR lie at the other extreme and exhibit
a high basal level of activity in the absence of ligand (41, 42).
To investigate how the balance between repression and ac-
tivation is encoded in the ligand binding domain of the recep-
tor, we used a mutagenesis approach to look for residues that
differentially affect co-repressor and co-activator recruitment
to RAR. We characterized the interaction of these mutant re-
ceptors with co-activators and co-repressors using a mamma-
lian two-hybrid approach and in vitro interaction analyses such
as GST pull-down assays and DNA bandshift assays. The in-
herent transcriptional activity of the mutant receptors was also
determined using transient transfection reporter gene assays.
We found that mutation of the majority of the residues within
the proposed co-repressor and co-activator docking sites re-
duced the binding of both co-activator and co-repressor. These
can be viewed as simple docking site mutations. Two mutations
behaved very differently in that the effects on co-repressor and
co-activator binding were reversed, and the basal activity of the
receptor was dramatically changed.
MATERIALS AND METHODS
Cell Culture and Reagents—The CV-1 (green monkey kidney fibro-
blast) cell line was used for all transfection studies. Cells were main-
tained in Dulbecco’s modified essential medium supplemented with
10% fetal calf serum (Invitrogen), 2 mM glutamine, penicillin, and
streptomycin (Sigma). The day before transfection 1  106 cells were
plated into 48-well plates.
Transient Co-transfection and Luciferase/-Galactosidase Assay—
Cells were transfected at 60–80% confluency using 1,2-dioleoyl-3-tri-
methyl ammonium-propane (Avanti Polar-Lipids, Inc.) as described
previously (18, 43). Transfection was carried out in Dulbecco’s modified
essential medium containing 5% charcoal-stripped, delipidated bovine
calf serum (Sigma). After 6–8 h, the medium was changed to Dulbecco’s
modified essential medium containing the indicated ligands or vehicle.
Cells were lysed and assayed for reporter expression 24 h after trans-
fection. The luciferase assay system (Promega) was used according to
the manufacturer’s instruction. The -galactosidase activity was deter-
mined as described previously (27). Measurements were made using a
Wallac, Victor-2, multilabel counter. Luciferase activity of each sample
was normalized according to the -galactosidase activity. Each trans-
fection was carried out in triplicate and repeated three to six times.
Plasmids and Mutagenesis—Mammalian expression vectors express-
ing Gal-hSMRT-ID-1, -ID-2, -ID-12, Gal-hRAR-LBD, VP-hRAR-
LBD, CMX-hRXR-LBD, CMX-hRXR-FL, CMX-hRAR-FL, GST-C-
SMRT, pMH100-TK-luc, and pCMX--galactosidase were described
previously (18). The Gal-DRIP-ID-12 expression plasmid contained
residues 527–775 of DRIP cloned into the vector pCMX-Gal4-DBD.
Mutations within the VP-hRAR-LBD, VP-hTR-LBD, Gal-hRAR-
LBD, and CMX-hRAR-FL were obtained using the methods described
in the QuikChange site-directed mutagenesis kit (Stratagene). All con-
structs were verified by DNA sequence analysis (DNA sequencing kit,
BigDye Terminator Cycle Sequencing version 2.0, and ABI 310 se-
quence analyzer). Plasmids were grown in Escherichia coli strain
DH5. DNA was extracted and purified using Qiagen Maxi or Midi
columns or Promega MiniPrep kit.
Protein Expression and Purification—GST fusion proteins were ex-
pressed and purified as described previously (27). Briefly, proteins were
expressed in E. coli strain BL21. The cells were lysed by sonication, and
the protein was purified using a glutathione-Sepharose 4B affinity
column (Amersham Biosciences) in buffer containing 50 mM Tris (pH
8.0), 1% Triton X-100, and 1 mM 4-(2-aminoethyl)benzenesulfonyl fluo-
ride. Bound proteins were eluted with 10 mM glutathione in 50 mM
phosphate-buffered saline.
Ligand Binding Assay—Ligand binding assays were performed us-
ing bacterially expressed GST-hRAR-LBD fusion proteins and radio-
labeled 9-cis-[3H]retinoic acid. For the saturation binding analysis,
purified receptor protein was incubated for 1 h at room temperature in
binding buffer (20 mM Tris-HCl, 50 mM KCl, 1 mM MgCl2, 1 mM dithi-
othreitol, pH 8.0) with increasing amounts of 9-cis-[3H]retinoic acid.
Bound ligand was separated from free ligand on chromatography col-
umns (Bio Spin 30 Tris columns, Bio-Rad). Binding affinities were
calculated using Scatchard analysis from three separate experiments
on independently generated protein samples.
GST Pull-down—hRAR-LBD mutant proteins were synthesized us-
ing a T7 Quick TNT in vitro transcription/translation kit (Promega)
with [35S]methionine. 35S-Labeled proteins were incubated with GST
fusion protein (bound to glutathione-Sepharose 4B resin) in the pres-
ence or absence of (E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-
(naphtylenyl)-1-propenyl] benzoic acid (2.5 M) for 2 h at room temper-
ature. After centrifugation, the beads were washed twice with
phosphate-buffered saline buffer containing 0.1% Triton X-100 and 1
mg/ml bovine serum albumin and resuspended in 2 Laemmli buffer
(27). After centrifugation, the proteins were analyzed by SDS-PAGE
and visualized/quantified using an image plate scanner (Typhoon, Am-
ersham Biosciences).
Electrophoretic Mobility Shift Assays—Full-length hRAR and
hRXR receptors were produced using the T7 Quick TNT in vitro tran-
scription/translation kit (Promega). The electrophoretic mobility shift
assay probe DNA (RARE-DR5) was prepared by annealing complemen-
tary oligonucleotides and was labeled with [32P]dCTP using reverse
transcriptase. The RARE-DR5 probe (5-CGTTGGCGCCGGGTCAC
CGAAAGGTCAGAATTAG-3) was incubated with the receptors and
bacterially expressed SMRT in binding buffer (20 mM HEPES, pH 7.5,
75 mM KCl, 0.1% Nonidet P-40, 7.5% glycerol, 2 mM dithiothreitol) in
the absence or presence of receptor-specific ligands for 20 min at room
temperature. Samples were analyzed using a 10- 10-cm, 0.7% agarose
gel buffered in 0.5 Tris borate. Bold, underlined residues indicate the
consensus binding site. The gel was dried and visualized using an image
plate scanner (Typhoon, Amersham Biosciences).
RESULTS
Analysis of SMRT RID RAR-LBD Interactions—Previous do-
main mapping studies of the co-repressor SMRT have shown
that the protein contains two receptor interaction domains,
ID-1 and ID-2 (44). To determine whether one or both IDs are
necessary for interaction with the ligand binding domain of
RAR, a mammalian two-hybrid assay was established in CV-1
cells. SMRT interaction domains were fused to the Gal4 DNA
binding domain and challenged with the RAR-LBD fused to a
VP16 activation domain. Fig. 1 shows that SMRT ID-12 in-
teracts strongly with the RAR-LBD and that this interaction is
abolished by treatment with AM580, an RAR selective ago-
nist. The isolated SMRT ID-2 essentially recapitulated the
ligand-dependent behavior of SMRT ID-12, whereas the as-
say failed to detect any interaction with the isolated SMRT
ID-1 alone.
To test whether the domain specificity remains in the context
of the combined interaction domain, which includes both ID-1
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and ID-2, we used point mutations to remove conserved hydro-
phobic amino acids from the individual IDs (27). SMRT ID-12
harboring mutations in ID-1 behaved exactly like the isolated
ID-2, and similarly, SMRT ID-12 with mutations in ID-2
behaved like the isolated domain of ID-1. Interestingly the
combined RID domain (SMRT ID-12) showed a stronger in-
teraction than ID-2 alone, either as an isolated domain or as an
ID-1 mutant. This suggests that ID-1 may contribute to ID-
2RAR-LBD interaction, although it does not appear to facili-
tate direct binding to the LBD. These experiments also estab-
lished that ID-2 is the primary site on SMRT for interaction
with RAR-LBD and that it is necessary and sufficient for ligand
sensitive interaction.
Mutational Analysis of RAR-LBD Co-repressor Interac-
tions—To gain insight into the molecular determinants of co-
repressor binding on the surface of the RAR-LBD, we made a
series of specific point mutations of surface residues of the
RAR-LBD. 17 residues were selected as being potentially im-
portant for the co-repressorreceptor interaction by inspection
of the available crystal structures and analysis of the conser-
vation between different receptors. These residues lie on heli-
ces 3 and 4 (Trp-225, Ser-229, Ser-233, Ile-236, Val-240, Lys-
244, Gly-248, Phe-249, Thr-250, Ile-254, Gln-257, Ile-258, and
Leu-261), helix 5 (Cys-265 and Leu-266), and helix 11 (Ala-392
and Val-395) (Fig. 2, A and B). Mutations in several of these
residues have been analyzed in previous studies and serve as a
reference in our analysis (Fig. 2, A and B). Mutations were
generated by standard mutagenesis technology, then se-
quenced, and tested in mammalian two-hybrid interaction as-
says for interaction with SMRT ID-2. The mutant receptors can
be grouped into different categories based on the strength of
their interaction with SMRT ID-2 in the presence or absence of
a RAR selective ligand. Mutants such as S229A, T233A,
I258A, and C265A behaved very similarly to the wild type
receptor with a strong interaction in the absence of ligand that
was abolished on addition of ligand. The majority of the mu-
tants (G248A, F249A, T250A, I254A, A392R, and V395A)
showed a significantly reduced, ligand-sensitive interaction.
Several others such as I236A, V240A, K244A, Q257A, and
L266A showed very little or no interaction at all. One particu-
lar mutant, W225A, showed an interaction with co-repressor
protein equally as strong as the wild type receptor but was
completely unable to release the co-repressor upon ligand bind-
ing. In contrast the L261A mutant exhibited increased inter-
action with SMRT in the presence of ligand.
Interaction of RAR-LBDRXR-LBD Heterodimers with
SMRT RID—RAR functions as a heterodimeric complex with
RXR. To recapitulate the SMRTRAR interaction in a more
physiological context, we examined the effects of the RAR mu-
tations in the presence of RXR and both SMRT IDs. Fig. 3A
shows that for the wild type receptor there is no significant
difference between monomer and heterodimer in the interac-
tions with SMRT ID-12. Neither the strength of interaction
nor its ligand sensitivity was altered suggesting that RXR does
not contribute to or alter the RAR-LBD SMRT interaction per
se. Based on these findings we rescreened the RAR-LBD mu-
tants in the heterodimer assay system (Fig. 3B). Only three
mutants, G248A, L261A, and L266A, behaved differently from
the assay with the RAR-LBD alone (compare Fig. 3B to Fig.
2C). These mutants regained wild type-like activity suggesting
that RXR may stabilize RAR-LBDSMRT-RID interactions
leading to wild type-like cofactor binding activity. This also
means that the heterodimer assay is more stringent for assess-
ing the effects of mutations on co-repressor binding since it is
likely that some folding instability generated by certain muta-
tions may be overcome by RXR acting as a chaperone.
While mammalian two-hybrid analysis is a sensitive and
quantitative way of measuring interactions, we sought to con-
firm these results in an in vitro interaction assay. GST pull-
down experiments were performed using bacterially expressed
GST-SMRT ID-12 protein and radiolabeled RAR-LBD. In this
assay (Fig. 3C) we found that the mutants behaved essentially
identically to the mammalian two-hybrid assay. Significantly
the mutant W225A, which showed wild type-like interaction
with SMRT but no ligand-sensitive release of SMRT ID-12,
behaved exactly the same way in the in vitro assay. Mutant
A392R on the other hand showed a much weaker ligand-sen-
sitive interaction with the co-repressor than did wild type.
These analyses are consistent with previous studies on other
receptors, which show that the primary co-repressor binding
site on RAR is a hydrophobic groove between helices 3 and 4
(32, 36, 38). Mutations on this surface of the LBD such as
I236A, V240A, K244A, F249A, T250A, I254A, Q257A, and
I258A abolished or significantly reduced co-repressor binding.
Two mutations, W225A and A392R, lie outside this region.
W225A interacted with SMRT ID-2 more strongly than did wild
type receptor, and this interaction was ligand-insensitive. In
contrast the A392R mutation showed a markedly reduced in-
teraction with co-repressor.
Analysis of Co-activator Binding—The premise of our studies
was that the co-repressor and co-activator binding sites are
largely overlapping. Therefore we sought to establish a co-
activator binding assay using the previously identified receptor
FIG. 1. Interaction of SMRT IDs with RAR-LBD. Interaction
analysis of SMRT IDs and RAR-LBD was carried out using mammalian
two-hybrid assays as described under “Materials and Methods.” The
strength of interactions is expressed as normalized luciferase activity.
The mean of at least three independent measurements  S.D. is pre-
sented. A, interactions of Gal-RAR-LBD with VP-SMRT-ID-12, -ID-2,
and -ID-1 in the presence and absence of AM580 (100 nM). B, upper
panel, shows the amino acid sequence of SMRT ID-12 interaction
domains; lowercase indicates the mutations in ID-1 (mID-1) and ID-2
(mID-2). The lower panel shows the comparison of the strength of
interactions of wild type and mutant forms of Gal-SMRT-ID-12 with
VP-RAR-LBD. AU, arbitrary units.
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interaction domains of two co-activators: ACTR and DRIP205/
TRAP220. These have both been shown to directly interact
with RAR, and they represent distinct classes of co-activator
proteins (45). Mammalian two-hybrid analyses were performed
using Gal4-DBD fusions of the receptor interacting domains
from DRIP205/TRAP220 and ACTR (12, 46, 47) and VP-RAR-
LBD fusion proteins in the presence of co-transfected RXR-
LBD. The strength of interaction of the various mutants with
DRIP205/TRAP220 ID has been plotted relative to that of the
wild type receptor (Fig. 4A). It is interesting to note that in all
cases the binding of the RARRXR heterodimer is 2-fold
higher than that of the VP-RAR-LBD alone. Some of the mu-
tants (S229A, T233A, I236A, G248A, T250A, C265A, L266A,
and V395A) behaved like wild type, whereas W225A, V240A,
K244A, F249A, I254A, Q257A, I258A, and L261A showed re-
duced co-activator binding. Remarkably one mutant (A392R)
showed significantly increased DRIP205/TRAP220 binding.
This mutant, if compared with wild type, shows an increased
co-activator binding even in the absence of ligand, which fur-
ther increases almost 2-fold in the presence of ligand (Fig. 4B).
Note that although the two co-activators ACTR and DRIP205/
TRAP220 are not related there was no significant difference in
binding (data not shown) suggesting that the two co-activators
are likely to bind to the same site on the receptor.
To summarize the various mutants, we grouped them based
on their cofactor binding profile as shown in the diagram on
FIG. 2. Interaction of RAR-LBD mu-
tants with SMRT IDs. A, sequence
alignment of the LBD of different nuclear
receptors (hRAR, hRXR, hTR, and
hPPAR). Gray boxes show the amino
acid residues that were mutated. The sec-
ondary structure elements (-helices (H))
are boxed in black. Amino acids mutated
by others are indicated by stars (27–29).
B, surface and ribbon representation of
the RAR-LBD (Protein Data Bank code
2LBD). Residues on helix 3, helix 4, helix
5, and helix 11 mutated in this study are
shown in red and labeled. The ligand
ATRA is shown in green. Helix 12 is
shown in yellow. The mutated residues
form a cluster on the surface of RAR-LBD.
C, mammalian two-hybrid analysis of the
interaction of VP-RAR-LBD mutants with
Gal-SMRT-ID-2 in the presence or ab-
sence of AM580 (100 nM). The strength of
interactions is expressed as normalized
luciferase activity. The mean of at least
three independent measurements  S.D.
is presented. AU, arbitrary units.
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Fig. 4C. The majority (ten) of the mutants showed reduced
co-repressor binding, and six of them showed a combined co-
repressor co-activator binding deficiency. There were a few
mutants (I236A, T250A, and V395A) that showed a reduced
ability to bind co-repressor, and there was only one (L261A)
with solely reduced co-activator binding. The existence of these
mutants (i.e. mutants that selectively reduce co-activator or
co-repressor binding to the RAR-LBD) may be evidence that
the co-activator and co-repressor binding surfaces do not com-
pletely overlap. Intriguingly we found two mutations, W225A
and A392R, each of which inversely affects co-activator and
co-repressor binding. Since both of these mutants are located
outside of the mapped and proposed docking site for cofactors
we believe that these two mutants do not alter the binding site
per se but represent mutations of an intrinsic regulatory site.
In Fig. 4D the various mutations that affect both co-activator
and co-repressor binding on the structure are color-coded. Res-
idues that, when mutated, reduced both co-activator and co-
repressor binding are shown in blue and represent the cofactor
binding surface or docking site. Residues in cyan reduced co-
repressor binding but not co-activator binding. The magenta
residue Leu-261, if mutated to alanine, reduced co-activator
binding without altering co-repressor binding. Mutation of Trp-
225 (in red on the right) increased co-repressor binding and
diminished co-activator binding, while Ala-392 (in red on the
left), if mutated to arginine, reduced co-repressor binding but
enhanced co-activator binding. In general it appears that mu-
tations within the binding/docking site reduce both co-activator
and co-repressor binding. Mutations outside this area, in close
proximity of helix 12, differentially influence co-activator and
co-repressor binding.
Transcriptional Activity of the Mutant Receptors—It is im-
portant to understand whether the transcriptional activity of a
nuclear receptor is determined simply from the cofactor bind-
ing profile. If this is the case, we would predict that receptors
with combined co-activator/co-repressor mutations (docking
site mutations) would be transcriptionally inert as a result of
losing some or most of their ability to repress as well as to
activate but that their basal transcriptional activity would be
similar to that of the wild type receptor. On the other hand,
regulatory mutations that differentially affect co-activator and
co-repressor association could produce receptors that can either
repress or activate transcription significantly beyond the nor-
mal range of wild type receptor. To explore this possibility we
carefully examined whether, and how, selected mutations af-
fect the transcriptional activity of the Gal4-DBD-fused and
full-length receptors. We considered this to be a critical test of
the hypothesis that the cofactor binding and release profile has
a predictive value on overall transcriptional activity. Six mu-
tants were compared: three were deficient in both co-activator
and co-repressor binding (V240A, K244A, and I254A), and
three other ones differentially affected cofactor association
(W225A, A392R, and V395A).
Fig. 5A shows the activity of wild type and mutant receptor
LBDs (fused to the Gal4-DBD) in the absence of exogenous
ligand. In this experiment wild type receptor repressed tran-
scription of the reporter gene by 50%. W225A repressed tran-
scription significantly more strongly than wild type (95%).
The K244A and V395A mutants showed no repression activity
at all. The V240A and I254A mutants also showed a reduced
repressor activity compared with wild type (28 and 14% of the
basal activity of the reporter gene, respectively). Strikingly the
A392R mutant produced a very significant increase in activity
of the reporter gene. Thus, rather than repressing basal tran-
scription, this mutant acts as a constitutive activator.
Next we examined the response of the wild type and mutant
chimeric receptors to an increasing dose of AM580 to assess the
ligand-inducible transcriptional activity (Fig. 5B). The wild
FIG. 3. Interaction of RAR-LBD mu-
tants with SMRT ID-12 in the pres-
ence of RXR-LBD. Interaction between
SMRT ID-12 and RAR-LBD mutants in
the presence of RXR-LBD was deter-
mined using mammalian two-hybrid
analysis (A and B) or GST pull-down as-
say (C). For the mammalian two-hybrid
analysis the strength of interactions is
expressed as normalized luciferase activ-
ity. The mean of at least three independ-
ent measurements S.D. is presented. A,
interaction of Gal-SMRT-ID-12 with
VP-RAR-LBD  RXR-LBD and AM580
(100 nM). B, interaction of Gal-SMRT-ID-
12 with mutant RAR-LBDs in a het-
erodimer with RXR-LBD in the presence
and absence of AM580 (100 nM). C, GST
pull-down analysis showing interaction of
RAR-LBD mutants with GST-SMRT-ID-2
in the presence or absence of (E)-4-[2-
(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-
naphtylenyl)-1-propenyl] benzoic acid
(TTNPB) (100 nM). The lower panel shows
the specific binding of in vitro translated,
[35S]methionine-labeled receptors on
GST-SMRT-ID-12 matrix analyzed by
SDS-PAGE (as described under “Material
and Methods”), visualized by autoradiog-
raphy, and then analyzed by densitome-
try (upper panel). Results are presented
as the specific binding to GST-SMRT-ID-2
in arbitrary units (AU). 10% of the labeled
protein input is shown in the lower panel.
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FIG. 4. Characterization of co-activator binding by monomer and heterodimer mutant RAR-LBDs. Interaction analysis of Gal-
DRIP205/TRAP220 fusion proteins and wild type and mutant VP-RAR-LBD chimeric receptors was carried out in mammalian two-hybrid assays.
The strength of interactions is expressed as normalized luciferase activity. The mean of at least three independent measurements  S.D. is
presented. A, upper panel, shows interaction of Gal-DRIP205/TRAP220-RIDs with VP-RAR-LBD mutants in monomer (gray column) and
heterodimer (black column) studies in the presence of AM580 (100 nM). Binding is expressed as the percentage of binding observed for the wild type
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type RAR-LBD showed a dose-response curve with a half-max-
imal induction (EC50) at 7 nM AM580. The I254A and V395A
mutants have an EC50 similar to that of the wild type, although
the amplitude of induction was significantly lower. In contrast,
W225A and K244A did not activate transcription to any signif-
icant degree. As expected, the A392R mutation showed an
increased basal activity and interestingly exhibited a larger
amplitude of induction by AM580.
To ascertain whether RXR has an effect on the transactiva-
tion activity of the mutant receptors, we co-transfected a plas-
mid that expresses the RXR-LBD (Fig. 5C). Interestingly the
A392R mutant showed an altered activity in this assay: its
constitutive activity in the absence of ligand was significantly
reduced, and it showed an unexpected increased potency for
AM580 (EC50  1.5 nM). The only other mutant to behave
significantly differently in the presence of the RXR-LBD was
V240A. This mutant was totally inactive as a monomer but
regained some transcriptional activity in the presence of RXR.
However, this mutant remains at least an order of a magnitude
less sensitive to AM580 than the wild type receptor (Fig. 5C).
Finally, to examine the effect of mutations in the most phys-
iological setting possible, we examined the behavior of the
full-length RXRRAR heterodimer bound to a natural response
element. Transient transfection assays were performed, in the
presence of increasing AM580, using full-length RAR (wild type
and mutant), full-length RXR, and a  RARE-TK-luc reporter
gene. Wild type and the V395A mutant receptors showed a
dose-dependent transactivation profile with an EC50 of 6.7 and
5.5 nM, respectively (Fig. 5D). In the same assay the W225A
mutant showed no significant transactivation, while the A392R
remained more potent than wild type receptor as indicated by
the dose-response curve shifting to the left (EC50  0.9 nM).
Electrophoretic Mobility Shift Assay Analysis of Mutant Re-
ceptors—Electrophoretic mobility shift analysis was used to
verify that the full-length receptors behave the same way in an
in vitro assay. The full-length RARRXR heterodimer (ex-
pressed in an in vitro transcription/translation system) formed
a specific complex with the radiolabeled  RARE probe (Fig. 6).
Addition of SMRT ID-12 (expressed in bacteria) gave a clear
supershift. As expected, the co-repressor was not dissociated by
the RXR-specific ligand LG100268 but was readily dissociated
on addition of AM580 (Fig. 6). Compared with the wild type
RAR-LBD (in the presence of ligand) in the same assay. The lower panel is the schematic representation of the two nuclear receptor box motifs (NRI
and NRII) in the full-length DRIP 205/TRAP220 (amino acids 1–1566) and RIDs for ACTR (amino acids 1–1412) used in the two-hybrid assays.
B, interaction of DRIP205/TRAP220 with wild type and A392R mutant RAR in the presence or absence of AM580 (100 nM). C, Venn diagram
showing the altered co-activator and co-repressor interactions of RAR mutants. D, surface and ribbon representation of the RAR-LBD (Protein
Data Bank code 2LBD). Residues on helix 3, helix 4, helix 5, and helix 11 mutated in this study are colored according to their effect on cofactor
binding. Blue indicates impaired binding of co-activator and co-repressor, cyan indicates impaired binding of co-repressor only, magenta indicates
impaired binding of co-activator only, and red indicates residues that differentially influence cofactor binding. The ligand ATRA is shown in green.
Helix 12 is shown in yellow. AU, arbitrary units.
FIG. 5. Transcriptional activity of mutant receptors. The transcriptional consequences of selected mutations were determined using
transient transfection assays. Transient co-transfection assays were carried out with the indicated plasmid constructs, and transcriptional activity
is expressed as normalized luciferase activity. Curves were fitted by Prism (GraphPad Prism Software, Inc.). A, transcriptional repression or
activation of unliganded RAR mutants. The broken line indicates the basal activity of the reporter construct. Representative experiments are
presented. Repression is expressed as the percentage of basal activity of reporter plasmids. B, dose-response curves of mutant Gal-RAR-LBDs upon
treatment with RAR-specific ligand AM580. C, dose-response curves of mutant Gal-RAR-LBDRXR-LBD heterodimers upon treatment with
AM580. The broken line indicates the basal activity of the reporter construct. D, dose-response curves of full-length RARRXR heterodimers
co-transfected with  RARE-TK-LUC upon AM580 treatment. The broken line indicates the basal activity of the reporter construct. AU, arbitrary
units.
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receptor, W225A bound SMRT ID-12 more strongly, and this
interaction was not dissociated by either ligand. T250A and
A392R showed co-repressor binding activity similar to that of
wild type, consistent with the results obtained in previous
experiments (Fig. 5).
Homologous Mutations in hTR Have Effects Similar to
Those in hRAR—Finally we reasoned that, if the two residues
(Trp-225 and Ala-392) represent functionally conserved amino
acids contributing to the balance of co-repressor and co-activa-
tor binding to receptor LBDs, then mutations of the analogous
amino acids in a different receptor should have similar effects.
We chose hTR because it is the closest homologue of RAR and
is a strong transcriptional repressor. Analogous mutations
(F264A and A431R) were made in VP16 fusions of the hTR-
LBD, and interaction with Gal-SMRT-ID-12 was measured
using transient transfection assays. F264A interacted with
co-repressor almost twice as strongly as the wild type, while
A431R showed a somewhat reduced interaction (75% of the
wild type, Fig. 7). These results were comparable to the equiv-
alent mutations in RAR. Moreover, upon ligand (triiodothyro-
nine) treatment, the interaction of the F264A mutant with
SMRT was hardly affected by ligand. In contrast A431R was
more sensitive to ligand than was wild type. We also noted that
ligand failed to completely release SMRT ID-12 from hTR
F264A. These data collectively suggest that analogous mutants
in TR show a similar phenotype to those described in RAR
further underscoring the notion that the identified residues are
functionally conserved.
DISCUSSION
Transcriptional activation by nuclear receptors depends crit-
ically upon the balance of cofactor recruitment. In the cellular
environment, multiple co-repressor and co-activator proteins
are available to interact with nuclear receptors. It is the bal-
ance between the two that determines the transcriptional out-
come. This balance is specific for each receptor and is controlled
both by ligand and by the availability of specific cofactors. The
biological significance of this interplay of factors has been high-
lighted by Brown and colleagues (48) who have elegantly shown
that for the estrogen receptor the tissue-selective response for
selective estrogen receptor modulators (SERMS) is a conse-
quence of the specific balance between co-activators and co-
repressors in a particular cell type.
Structural studies have provided a static view of both co-
activator and co-repressor complexes with various nuclear re-
ceptors (24–26, 32). Xu et al. (32) provided the first structural
evidence that the co-repressor and co-activator binding sites
are indeed largely overlapping. These studies combined with
biochemical analyses suggest that the two types of cofactors
bind in a very similar fashion to a conserved surface on the
receptor ligand binding domain. They also reveal that co-acti-
vator binding requires that helix 12 be in the active position
and conversely that co-repressor binding requires that helix 12
is displaced from the active position. In some, but not all,
receptors it is clear that ligand directly stabilizes the active
conformation of helix 12 and therefore promotes co-activator
recruitment. While these studies have been very revealing,
they leave unanswered the question of what determines the
basal activity of different receptors. Why do some receptors
such as TR and RAR strongly repress transcription in the
absence of ligand, and why do others such as PPAR show a
basal transcriptional activity? In other words what are the
intrinsic determinants of cofactor binding balance?
To explore this we first established a simple co-repressor and
co-activator interaction assay using mammalian two-hybrid
analysis. We demonstrated that ID-2 of SMRT is necessary and
sufficient to mediate interaction between the RAR-LBD and
SMRT. We then sought to identify mutations that would alter
the balance between co-repressor and co-activator binding and
thus alter the intrinsic basal activity of the receptor.
Identification of a Passive Docking Site for Cofactor Bind-
ing—Consistent with previous mutagenesis and structural
studies, we found that mutations in helices 3 and 4 disrupt both
FIG. 7. Interaction of SMRT ID-12 with TR mutants contain-
ing mutations equivalent to RAR-LBD W225A and A392R. VP16
fusion proteins of hTR-LBD (wild type and F264A and A431R, equiv-
alent to W225A and A392R in RAR) were tested for interaction with
Gal-SMRT-ID-12 in mammalian two-hybrid analysis. Transient
transfections of VP16 fusion hTR mutants were carried out in the
presence of increasing amounts of triiodothyronine (T3). The strength of
interactions is expressed as normalized luciferase activity; representa-
tive experiments are shown. Curves were fitted by Prism (GraphPad
Prism Software, Inc.). AU, arbitrary units.
FIG. 6. Electrophoretic mobility shift analysis of wild type and mutant full-length RARRXR heterodimers. Electrophoretic mobility
shift analysis was performed with in vitro translated RAR-FL, RXR-FL, and bacterially expressed GST-SMRT-ID-12. These were bound to
32P-labeled RARE-DR5 oligonucleotide in the presence or absence of the indicated ligands at a concentration of 500 nM. Arrows indicate the position
of the two specific complexes.
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co-activator and co-repressor binding. It appears therefore,
that while the RAR-LBD interacts preferentially with SMRT
ID-2 (rather than ID-1 like other tested receptors), the inter-
action is analogous to that between SMRT ID-1 and other
receptors. Significantly the majority of mutations made on this
cofactor binding surface of the receptor perturbed both co-
activator and co-repressor binding. This clearly indicates that
the binding sites are largely overlapping. However, a number of
residues were found to selectively perturb co-repressor binding
(Ile-236, Thr-250, and Val-395). In contrast, mutation of Leu-
261 reduced only co-activator binding without influencing co-
repressor interaction. We also noted that this mutant induced
co-repressor interaction in the presence of RAR ligand. It is
important to note, however, that these differences do not trans-
late into substantive differences in transcriptional activity and
suggest that any mutation of this surface leads to transcrip-
tionally inert receptor even if the co-repressors and co-activa-
tors are not evenly affected (i.e. V395A, Fig. 5).
Residues That Determine the Basal Activity of the Receptor—
While the majority of mutations resulted in only modest
changes to the balance between co-repressor and co-activator
binding, a second class of mutations led to dramatic differences
with respect to the different cofactors. It is striking that these
mutations are not located in the proposed docking site but
further away in the proximity of helix 12. Mutation of Trp-225
(in helix 3) to alanine resulted in a mutant with intrinsically
high affinity for co-repressor binding combined with very low
co-activator binding. This mutation significantly tips the bal-
ance toward co-repressor binding with almost total loss of co-
activator binding. Analysis of the transcriptional activity of
this receptor shows that, while it is still able to bind to ligand,
it acts as a constitutive repressor of transcription. Analysis of
the structure of the homologous RAR shows that Trp-225 is in
Van der Waals contact with residues in the loop between hel-
ices 11 and 12: Leu-398 (4.1 Å), Ile-402 (3.6 Å), Met-406 (3.5 Å)
and Pro-407 (3.9 Å) (Fig. 8A) (49, 50). It is generally difficult to
predict the structural consequences of mutations and espe-
cially so given the dynamic character of nuclear receptor ligand
binding domains (51). However, given the location of W225A,
the dominant negative phenotype, and the knowledge that
co-repressor binding requires the displacement of helix 12, it is
tempting to speculate that the W225A mutation may destabi-
lize the active position of helix 12 as a consequence of removing
the favorable contacts to the loop between helices 11 and 12.
This would in turn favor co-repressor interaction with the
mutant receptor and reduce the efficiency of release on binding
ligand. The importance of the loop between helices 11 and 12
has also been suggested by others (52). Significantly the effects
of this mutation are similar to those mutations in PPAR that
result in a receptor with dominant negative repression activity
(53) and that have been explicitly shown to destabilize helix 12
(54). It should be noted that Trp-225 makes only long range
Van der Waals contacts to the ligand, consistent with the
observation that the W225A mutant retains ligand binding
ability (125% of the wild type).
A second mutant that substantially changed the basal activ-
ity of RAR is A392R. This receptor showed minimal co-repres-
sor binding in conjunction with significantly increased co-acti-
vator binding activity. Again the ligand binding affinity
remained unchanged (135% of the wild type). As expected, this
receptor proved to be constitutively active, indicating that li-
gand binding per se is not required for transactivation, pro-
vided that there is an intrinsic ability to bind co-activator.
Again it is important to be cautious when trying to interpret
the effect of this mutation in the context of the ligand binding
domain structure, particularly given that this is a gain-of-
function mutation. However, examination of the RAR struc-
ture shows that the larger Arg side chain could be sterically
accommodated at this position (Fig. 8B) (49). The larger argi-
nine side chain would, however, be in contact with a number of
residues in helices 4 and 12. These include Van der Waals
contacts to Leu-266 (3.3 Å) and Leu-414 (4.2 Å) as well as
hydrogen bonds to the side chain of Asn-416 in helix 12. It is
possible therefore, and would fit with the observed phenotype,
that the A392R mutation might stabilize the active conforma-
tion of helix 12 in the absence of ligand and hence promote
co-activator binding, which absolutely requires helix 12 in the
active position.
Significantly in PPAR the residue in this position is a va-
line. This side chain makes multiple Van der Waals contacts to
residues in helix 12 of PPAR (Tyr-473, Leu-476, and Tyr-477)
and thus stabilizes the active conformation of helix 12 in this
receptor (24). This correlates well with the observation that
PPAR does not repress transcription in the absence of ligand
but rather exhibits a high basal transcriptional activity. As
mentioned earlier this native behavior of PPAR closely
matches the behavior of the A392R mutant RAR.
Relatively Small Changes in Cofactor Binding Translate into
Large Changes in Transcriptional Activity—It is clear from the
analyses of these mutant receptors that the determination of
cofactor binding activity by mammalian two-hybrid analysis
has a high predictive value on the transcriptional activity of the
receptor. It is particularly striking that relatively small
changes in the cofactor binding potential translates into a large
shift in transcriptional activity (Fig. 5). In this respect the LBD
appears to function as a biological amplifier where small
changes affecting cofactor affinity result in significant biologi-
cal consequences (i.e. a constitutively active activator or repres-
sor). This notion further underscores the significance and
power of the intrinsic regulation of cofactor balance.
A Critical Role for Helix 12 in Determining Cofactor Equilib-
rium—In conclusion, these studies contribute to the emerging
view that the positioning, dynamics, and stability of the posi-
tion of helix 12 have a significant role in regulating transcrip-
tional activity of nuclear receptors (54). It has been shown
previously that helix 12 is required for transactivation (55, 56),
it contributes to the binding surface for co-activators (57), and
deletion or mutation of helix 12 results in dominant negative
receptors with increased co-repressor binding potential (58).
Our studies demonstrate that residues with the potential to
influence the stability of the active position of helix 12 control
the balance of the equilibrium between co-repressor and co-
FIG. 8. Residues Trp-225 and Ala-392 may influence the orien-
tation of helix 12 (H12). A, Trp-225 (red) is in Van der Waals contact
with several residues (green) in the loop between helices 11 (H11) and
12. Mutation of this residue to alanine may disfavor the active position
of helix 12 (yellow). The ligand ATRA is shown in magenta. The struc-
ture shown is that of RAR-LBD (Protein Data Bank code 2LBD). B,
mutation of Ala-392 to arginine (red) may stabilize the active position of
helix 12 (yellow) through contacts to helix 12. atRA, all-trans-retinoic
acid.
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activator binding. These findings also explain the differences in
basal activities between the various nuclear receptors and
clearly have implications for our understanding of the evolu-
tion of nuclear receptors with rather diverse properties. More-
over these results can be further exploited to design mutant
receptors with a much wider range of altered transcriptional
activity than was previously suspected.
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